NASS
Combined Meeting
ISMISS, ISS, IOSS

Meeting and Exhibition New Dates

Friday, Saturday, Sunday
October 8th – 10th, 2021.
09.00 - 17.00 UTC +7

Join Now

Congress Information

5th NASS Combined Meeting ISMISS, ISS, IOSS

October, 8th - 10th 2021

Virtual Conference and Exhibition

Important Dates

Deadline Abstract Submission : June 30th, 2021
Opening Ceremony : October 8th, 2021
Virtual Conference : October 8th - 10th 2021
Virtual Exhibition : October 8th - 10th 2021
Closing Ceremony : October 10th, 2021

Save the Date!


:::
DaysHoursMinutesSeconds
October, 8th - 10th 2021
Offer is ended

Organizing Committee

Patron:

  • President NASS
  • President ISS
  • President ISMISS
  • President IOSS
  • Dean FKK UMJ

Organizing Chairman:

  • DR. Dr. Bambang Darwono, SpB. SpOT (K)

Secretary :

  • Dr. Arsanto Triwidodo , SpOT(K). MHKes

Treasurer :

  • dr. Frans S. Hokardi

Scientific:

  • Prof. J.J. Abitbol, MD
  • Prof. DR. Dr. Angela B.M.Tulaar, SpKFR (K)
  • Prof. Dr. dr. Soehartati A. Gondhowiardjo, Sp.RadOnk (K)
  • DR. Dr. Agus Hadian Rahim, M.Epid, SpOT (K)
  • Dr. Tirza Z Tamin, SpKFR(K)
  • Dr. Arsanto Triwidodo , SpOT(K). MHKes
  • Dr. Syaifullah Asmiragani, Sp.OT(K)Spine
  • Dr. Zainy Hamzah, SpBS
  • Dr. Bambang Budyatmoko, SpRad(K)
  • Dr. A. Andi Kurniawan Sp.KO
  • Dr. Yudha Mathan Sakti, Sp.OT (K)




Scientific Program

Complete Scientific Schedule of NASS Combined Meeting ISMISS, ISS, IOSS.

Program at Glance

program at glance NASS Combined Meeting ISMISS, ISS, IOSS

See More Detail

Scientific Schedule

Complete Schedule NASS Combined Meeting ISMISS, ISS, IOSS

See More Detail

Registration

Registration Fee:

Registration Information

Registered participants are entitled to admission to all scientific sessions. Each participant will receive user id and password for access the virtual exhibition in this website and zoom webinar link with unique code ...

Read More...

Guideline for Abstract

To present free papers, you are required to be registered as a participant.

Please kindly pay attention to following guidelines:

  • There are two types of presentation: poster and oral (podium) presentation. Please select one of them. Please indicate your choice in the top corner of your abstract: Oral Presentation or E-Poster
  • Committee will decide on the final presentation type (oral presentation or E-Poster)
  • The abstracts should be within 300 words (maximum half A-4 size page) and the entire submission must fit on a single page.
  • Please Note: graphs / tables / images should not to be included in the abstract.
  • Abstracts should be prepared in Microsoft Word Arial, 12 point with single line spacing, typeface, with the title in boldface.
  • It is the author’s responsibility to submit a correct abstract. Any errors in spelling, grammar or scientific fact will be reproduced as typed by the author.
  • The abstract should have a short, specific title (containing no abbreviations) that indicates the nature of the investigation. Title should be in boldface font. The title should not exceed 20 words in UPPER CASE only.

  • File name format for Oral Presentation: Presenter name-abstract name-Oral
  • File name format for poster: Presenter name-abstract name E-Poster
  • For submission of abstract please send via email with attached Microsoft word file to nassismiss@pharma-pro.com or via online submission in this website, before the deadline in order to be sent for review and approval prior to its inclusion in the scientific program.
  • Last date for submission of abstract is ....
  • Notification of acceptance of abstracts submitted will be sent by e-mail at the latest by ....

  • Background/Rationale : Indicate the purpose and objective of the research, the hypothesis that was tested or a description of the problem being analyzed or evaluated.
  • Methods: Describe the setting/location for the study, study design, study population, data collection and methods of analysis used.
  • Results: Present as clearly and detailed as possible the findings/outcome of the study, with specific results in summarized form. Inclusion of gender breakdown of data is strongly encouraged.
  • Findings or Conclusion: briefly discuss the data and main outcome of the study. Do not begin sentences with numerals. Standard abbreviations may be used without definition.
Further Information
Congress

Secretariat

Ms. Sarah

Komplek Perkantoran Duta Merlin Blok C 35 - 38 Jl. Gajah Mada 3-5, Jakarta Pusat

nassismiss@pharma-pro.com

sarah@pharma-pro.com

+6221 – 63869502 | +62 817-0032-730